20 March 2018 - - Waltham, Massachusetts-based biotechnology company X-Chem, Inc. has appointed Christelle Huguet, Ph.D. as chief scientific officer, and Matthew Clark, Ph.D. as senior vice president, chemistry, the company said.
In the newly created position, Huguet will report directly into Rick Wagner, Ph.D, X-Chem's CEO. Huguet and Clark will be members of X-Chem's executive committee.
Huguet is a senior pharmaceutical research and development leader with over 20 years of industry experience. Most recently, Huguet was head of internal research at Alexion, focusing on rare and devastating diseases.
Prior to this, she spent 18 years at Pfizer running programs from the early phases of drug discovery to the early clinical development of programs through PhIIb. Huguet's most recent position at Pfizer was chief scientific officer, inflammation and remodeling unit.
Clark is a pioneer in the field of DNA encoded libraries of small molecules and is a founding scientist at X-Chem. He has overseen the development of the X-Chem DEX platform, including the creation of 200 bn molecules in X-Chem's screening library, along with the successful application of the platform that has led to 44 licensed programs to X-Chem's 22 active partnerships.
Privately owned X-Chem's mission is to apply its powerful product engine to the discovery of small molecule leads against high-value therapeutic targets. X-Chem has established partnerships with pharmaceutical companies, biotechnology organizations, and academic centers.